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ABSTRACT
MicroRNAs (miRNAs) are a class of small regulatory
RNAs that are thought to be involved in diverse bio-
logical processes by regulating gene expression.
Numerous miRNAs have been identified in various
species, and many more miRNAs remain to be
detected. Generally, hundreds of mRNAs have
been predicted to be potential targets of one
miRNA, so it is a great challenge to identify the gen-
uine miRNA targets. Here, we generated the cell
lines depleted of Drosha protein and screened
dozens of transcripts (including Cyclin D1) regulated
potentially by miRNA-mediated RNA silencing path-
way. On the basis of miRNA expressing library, we
established a miRNA targets reverse screening
method by using luciferase reporter assay. By this
method, we found that the expression of Cyclin D1
(CCND1) was regulated by miR-16 family directly,
and miR-16 induced G1 arrest in A549 cells partially
by CCND1. Furthermore, several other cell cycle
genes were revealed to be regulated by miR-16
family, including Cyclin D3 (CCND3), Cyclin E1
(CCNE1) and CDK6. Taken together, our data sug-
gests that miR-16 family triggers an accumulation of
cells in G0/G1 by silencing multiple cell cycle genes
simultaneously, rather than the individual target.
INTRODUCTION
MicroRNAs (miRNAs) areanextensive class ofsmallnon-
coding RNAs (18–25nt), with profound impact on many
biological processes in development, diﬀerentiation,
growth and metabolism by regulating gene expression.
miRNAs are initially transcribed as part of much
longer primary transcripts (termed pri-miRNAs) (1).
These primary transcripts are ﬁrst trimmed into approxi-
mate 70-nt stem-loop forms (called pre-miRNAs) by the
RNase III type endonucleases, Drosha, in the nucleus (2).
Followingthisinitialprocessing,pre-miRNAsareexported
fromthe nucleusto thecytoplasm byExportin5 (Exp5) and
processed to generate approximate 22-nt mature miRNAs
by Dicer, another RNase type III (3,4). Finally, the mature
single-stranded miRNA binds to proteins of the Argonaute
family to form the RNA–protein complex known as RNA-
induced silencing complex (RISC) (5,6).
miRNAs can regulate gene expression essentially by two
modes depending on the degree of complementarity with
the mRNA targets. In plants, miRNAs are often fully
complementary to their targets and elicit mRNA decay.
In contrast, most animal miRNAs are only partially com-
plementary to their targets and inhibit synthesis and func-
tion of proteins without aﬀecting transcript levels (7–9).
However, recent ﬁndings indicate that miRNAs can
induce substantial mRNA degradation even in the absence
of extensive base pairing to their targets (10,11). By reg-
ulating the expression of target genes, some miRNAs play
a crucial role in the initiation and progression of human
cancer. miR-15a and miR-16-1 are located at chromosome
13q14, a region deleted in more than half of B-cell chronic
lymphocytic leukemia (CLL). Detailed deletion and
expression analysis showed that miR-15a and miR-16-1
were located within a 30-kb region of loss in CLL,
and that both genes were deleted or downregulated in
 68% of CLL cases (12). Bottoni et al. (13) reported
that miR-15a and miR-16-1 were expressed at lower
levels in pituitary adenomas as compared to normal pitui-
tary tissue. Their expression was inversely correlated with
tumor diameter and with arginyl-tRNA synthetase expres-
sion, but was directly correlated with p43 secretion, sug-
gesting that these miRNAs might inﬂuence tumor growth.
Cimmino et al. (14) then demonstrated that miR-15a and
miR-16-1 expressions were inversely correlated to Bcl2
expression in CLL and negatively regulated Bcl2at a post-
transcriptional level. Bcl2 repression by miR-15a and
miR-16-1 induced apoptosis in a leukemic cell line
model. Therefore, miR-15 and miR-16 were natural anti-
sense Bcl2 interactors that could be used for therapy of
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miR-16 can regulate Nodal/activin signaling by targeting
the Nodal type II receptor Acvr2a, and restrict the size of
Spemann’s organizer in early Xenopus embryos (15).
Numerous miRNAs have been identiﬁed in diverse ani-
mals and plants. The miRNA database (16,17) currently
contains 533 human miRNAs (release 10.0), and many
more miRNAs may be still uncovered. In contrast to
the big number of validated miRNA sequences, only a
handful of comprehensive studies on miRNA function
have been completed. One of the biggest obstacles
to miRNAs function validation is the identiﬁcation of
their targets. Several computational algorithms have
been established to predict target genes of miRNAs.
According to these, a miRNA is generally thought to pos-
sibly have hundreds of or even to thousands of predicted
target genes (18), therefore, it is diﬃcult to determine
which one or ones is/are true targets regulated by the
miRNA to educe concrete biological functions. This
leads to great trouble on miRNAs function analysis.
Drosha is a key gene controlling miRNAs processing,
and its downregulation can inhibit the expression levels
of mature miRNAs and thus result in the upregulation
of their target mRNAs (via miRNAs mediating RNAi
mechanism). Therefore, the transcripts upregulated in
Drosha-depleted cells are probably the targets of
miRNAs. Likewise, Rehwinkel et al. (19) reported that
depletion of Drosha triggered upregulation of numerous
transcripts in Drosophila S2 cells, and many of these tran-
scripts were genuine targets of the miRNA pathway. For
those upregulated transcripts, computational algorithms
can be used to predict their potential controlling
miRNAs. Next, we can screen the miRNAs genuinely reg-
ulating these transcripts by using luciferase reporter assay.
Here, we established Drosha knockdown cell line and
identiﬁed a series of transcripts regulated potentially by
miRNA mediating RNAi mechanism. Among these can-
didate miRNA target transcripts, Cyclin D1 (CCND1) is a
cell cycle-related gene and plays a key role in controlling
G1/S transition. Moreover, it is a potential target for
tumor gene therapies. On the basis of miRNAs expression
library established (20), we developed a miRNA targets
reverse screening method using luciferase reporter assay.
By this method, CCND1 was found to be regulated by
miR-16 family. Furthermore, our research demonstrated
that miR-16 family regulated the expressions of several
other cell cycle genes, including CCND3, CCNE1 and
CDK6. All these data suggest that miR-16 family induces
G1 arrest by regulating multiple downstream eﬀectors
simultaneously.
MATERIALS AND METHODS
Plasmid construction
Drosha shRNA expressing plasmid was generated by
cloning annealed synthetic 63-mer oligonucleotides (See
Supplementary Material) (21) into BamHI and HindIII
sites within pSilencer hygro U6 vector (Ambion, Austin,
TX, USA).
Eukaryotic expression plasmids. DNA fragments coding
CCND1, CCND3, CCNE1 and CDK6 protein were
ampliﬁed by PCR from A549 cell cDNA, and cloned
into pIERS2-EGFP expression vector digested by XhoI
and BamHI or EcoRI.
Firefly luciferase reporter constructs. Wild-type 30 untrans-
lated regions (UTRs) containing predicted miRNA target
sites were ampliﬁed by PCR from HepG2 cell genomic
DNA. Mutant 30-UTRs were generated by overlap-
extension PCR method. Both wild-type and mutant
30-UTRs were cloned downstream of ﬁreﬂy luciferase
coding region between the XbaI and NdeI sites of a mod-
iﬁed pGL3-control plasmid (Promega, Madison, WI), as
described before (20).
Cell culture, transfection and preparation ofstable cell lines
HeLa, HepG2 and A549 cell lines were grown in
DMEM containing 10% FBS and 100mg/ml penicillin/
streptomycin. DNA transfection was performed with
FuGene HD transfection reagent (Roche, Indianapolis,
IN,USA) according to the manufacturer’s protocol. To
generate Drosha knockdown stable cell lines, HepG2
cells were transfected with pSilecer-U6-shDrosha and con-
trol plasmid. Cells were grown in the presence of 400ng/
ml hygromycin according to the manufacturer’s protocol
to select stably transfected clones. Single clone was
selected to generate monoclonal cell lines, and total
RNAs were extracted to test the knockdown eﬀects of
Drosha mRNA and miRNAs.
miRNAs, siRNAs and transfection
The miRNAs and siRNAs were designed and synthesized
by GenePharma (Shanghai, China) (See Supplementary
Material). siRNAs and miRNAs transfection were per-
formed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA,USA). In brief, cells were plated in 6-well plate to 40%
conﬂuence. For each well, 5ml siRNA or miRNA (20mM)
were added into 250ml Opti-MEM medium, 5mlo f
Lipofectamine 2000 into 250ml Opti-MEM medium and
then mixed siRNA or miRNA with Lipofectamine 2000.
The mixture was added to cells and incubated for 6h
before replacing the medium. Total RNA and protein
were prepared 48h after transfection and were used for
qRT–PCR or western blot analysis.
RNA extraction and qRT–PCR
Total RNA was extracted from the cultured cells using
Trizol Reagent (Invitrogen) according to the manufac-
turer’s protocol. qRT–PCR was used to conﬁrm the
expression levels of mRNAs and miRNAs. For mRNAs
detection, reverse transcription was performed according
to the protocol of Improm-II
TM Reverse Transcriptase
System (Promega); qPCR was performed as described in
the method of SYBR premix Ex Taq (TaKaRa, Dalian,
China) with Mx3000p (Stratagen, La Jolla, CA, USA)
supplied with analytical software. GAPDH mRNA
levels were used for normalization. For miRNAs detection
(22), total RNA was polyadenylated by poly(A) polymer-
ase (Ambion) ﬁrst. The 50ml polyadenylation reaction was
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merase according to the manufacturer’s protocol. The
reaction was incubated at 378C for 60min. After incuba-
tion, poly(A)-tailed total RNA was recovered by phenol/
chloroform extraction and ethanol precipitation. Reverse
transcription was performed using 1mg poly(A)-tailed
total RNA and 1mg RT primer(GCG AGC ACA GAA
TTA ATA CGA CTC ACT ATA GG(T)18VN) with
1ml Improm-II
TM Reverse Transcriptase according to
the manufacturer’s protocol; qPCR was performed as
described in the method of Quantitect SYBR Green
PCR Kit (Qiagen, Hilden, Germany) with Mx3000p
(Stratagene) supplied with analytical software. One
primer of miRNAs ampliﬁcation is miRNA speciﬁc, and
the other is a universal primer (GCG AGC ACA GAA
TTA ATA CGA C). U6 snRNA levels were used for
normalization.
mRNA microarrayanalysis
Stably transfected cells and normal HepG2 cells were har-
vested, and total RNA was extracted with Trizol reagent.
Total RNA (5mg) was reversely transcribed with the
cDNA Synthesis Kit (TaKaRa, Dalian, China) and
cRNA was produced by in vitro transcription (IVT) by
T7 RNA polymerase using T7 RiboMAX Express Large
Scale RNA Production System (Promega). cRNA (2mg)
was reversely transcribed by SuperscriptII reverse tran-
scriptase and 9-nt random primer. The products of reverse
transcription were labeled with klenow polymerase and
9-nt random primer. Labeled cDNA was hybridized
to 35k human Genome Array Genechips (CapitalBio,
Beijing, China). GenePix Pro 4.0 was used to analyze
the image of microarray, and the data were normalized
by the method of Lowess.
Western blot analysis
Protein extracts were prepared by a modiﬁed RIPA buﬀer
with 0.5% sodium dodecyl sulfate (SDS) in the
presence of proteinase inhibitor cocktail (Complete mini,
Roche, Indianapolis, IN, USA). Polyacrylamide gel elec-
trophoresis, tank-based transfer to Immobilon Hybond-C
membranes (Amersham Biosciences) and immunodetec-
tion were performed with standard techniques.
Antibodies against Drosha (sc-31159, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), CCND1
(K0062-3, MBL), CCND3 (K0013-3, MBL, Nagoya,
Japan), CCNE1 (K0172-3, MBL), CDK6 (K0006-3,
MBL), pRb (11131, Signalway antibody, Pearland, TX,
USA) and b-actin (sc-1616-R, Santa Cruz) were used in
western analysis in accordance with the manufacturer’s
instruction. Signals were visualized with SuperSignal
West Pico chemoluminescent substrate (Pierce,
Rockford, Ill, USA) by exposure to ﬁlms.
Luciferase assays
HepG2 cells were transfected in 24-well plates using
FuGene HD transfection reagent. The transfection mix-
tures contained 100ng of ﬁreﬂy luciferase reporter plasmid
and 400ng of plasmids expressing miRNA primary tran-
scripts. These plasmids expressing miRNAs come from a
miRNA expression library (20). pRL-TK (Promega) was
also transfected as a normalization control. Cells were
collected 48h after transfection, and luciferase activity
was measured using a dual-luciferase reporter assay
system (Promega).
Flow cytometry
Cells were transfected with miRNAs or siRNAs.
Nocodazole (100ng/ml; Sigma-Aldrich, St. Louis, MO,
USA) was added 24h after transfection, and cells were
further incubated for 20h. Floating and adherent cells
were harvested, combined, washed once in phosphate-
buﬀer saline (PBS), and ﬁxed in 70% ethanol overnight.
Staining for DNA content was performed with 50mg/ml
propidium iodide and 1mg/ml RNase A for 30min.
Analysis was performed on a FACScalibur ﬂow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) with Cell
Quest Pro software. Cell-cycle modeling was performed
with Modﬁt 3.0 software (Verity Software House,
Topsham, ME, USA).
Production of recombinant adenovirus andcell infection
DNA fragment containing miR-195 was ampliﬁed
from pcDNA-miR-195 (20), and cloned into pAdTrack-
CMV (23) digested with SalI and XbaI, generating
pAdTrack-CMV-miR-195. pAdTrack-CMV-miR-195
and pAdEasy-1 were homologously recombinated in
bacteria BJ5183. The newly recombinated plasmid,
pAd-miR-195, was tested by restriction endonuclease
digestions. Ad-miR-195 was propagated in HEK293
cells; viruses were collected from these cells, and stored
at  708C.
A549 cells were grown in DMEM containing 10% FBS
and 100mg/ml penicillin/streptomycin. For 24h prior to
infection, 3 10
5 A549 cells were plated in each well of
6-well plates, then infected with recombinant viruses
(Ad-miR-195 or Ad-empty) at a multiplicity of infection
(MOI) of 100 for 1h at 378C, followed by the addition of
fresh growth medium. Three days later, cells were har-
vested and cell cycles were analyzed by ﬂow cytometry.
RESULTS
Microarray analysis of transcripts regulated by miRNA
pathways
To screen the transcripts regulated by miRNA-mediated
RNA silencing pathway in genome wide, we constructed
the plasmid expressing shRNA targeting to Drosha ﬁrst.
To verify the knockdown eﬃciency, the plasmids were
transfected into HeLa cells. Results of semiquantitative
RT–PCR revealed that the level of Drosha mRNAs was
strongly reduced (Figure 1A). Then, plasmids expressing
the shRNA were transfected into HepG2 cells, and the
stably transfected cell clones were selected using hygro-
mycin. Quantitative RT–PCR was used to screen the
stable cell lines in which Drosha was strongly knocked
down (Figure 1B). qRT–PCR results indicated that
Drosha mRNA was reduced in all selected stable cell
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western blot (Figure 1C).
Drosha plays an important role in the processing of
miRNAs, so the maturation of miRNAs should be
repressed when Drosha was depleted (2,24). To analyze
the eﬀect of Drosha knockdown on miRNA expressions,
we detected the expression levels of three randomly
selected miRNAs by quantitative RT–PCR. As shown in
Figure 1D, the expression levels of miR-16, miR-31 and
miR-99a in clone 2 and clone 3 were reduced moderately
compared with normal HepG2 cells and control plasmid
transfected cells. The results above indicated that these cell
lines could be used to screen the transcripts regulated
by miRNA-mediated RNA silencing pathway globally.
To identify transcripts whose levels are regulated by the
miRNA pathway in HepG2 cells, we analyzed Drosha
knockdown stable cell line, control plasmid stably trans-
fected cell line and normal HepG2 cells using 35k human
Genome Array (CapitalBio Corporation, Beijing, China).
Table 1 summarizes analysis of transcripts changing
expression levels upon knockdown of Drosha. We
observed that there were 781 transcripts at least 1.5-fold
upregulated in Drosha-depleted cells compared with
normal HepG2 cells, and 558 transcripts compared with
control plasmid stably transfected HepG2 cells. However,
there were only 281 or 153 transcripts 2-fold upregulated
compared with normal HepG2 cells or control stably
transfected cells. The bulk of upregulated transcripts
changed slightly (<2-fold) at the mRNA level, suggesting
that miRNAs generally have a tuning role in regulating
gene expression.
Since inhibition of the miRNA pathway correlates with
increased abundance of mRNAs targeted by miRNAs, the
transcripts upregulated in Drosha-depleted cells may
represent putative miRNA targets. Compared with
normal HepG2 cells or control stably transfected cells,
there were respectively 281 and 153 transcripts upregu-
lated signiﬁcantly in Drosha-depleted cells, in which 53
transcripts overlapped. We deﬁned these 53 mRNAs as
core transcripts, whose levels were potentially regulated
by the miRNA pathway, that is, these mRNAs were
potential miRNA targets. Besides, these transcripts repre-
sented 45 genes (Table 2), and they did not exhibit any
apparent functional relationship.
As shown in Table 2, CCND1 was upregulated sig-
niﬁcantly in Drosha-depleted cells, which suggested
CCND1 was a potential miRNA target. Cyclin D1, the
product of CCND1 gene, is an important regulator of G1
to S phase progression in many diﬀerent cell types. Cyclin
D1, together with its binding partners cyclin-dependent
kinase 4 and 6 (CDK4 and CDK6), forms active com-
plexes that promote cell cycle progression by phosphory-
lating and inactivating the retinoblastoma protein (Rb)
(25). In many human cancers, including parathyroid
Figure 1. Generation and characterization of Drosha knockdown stable cell lines. (A) The eﬀectiveness of Drosha depletion was analyzed by semi-
quantitative RT–PCR. Normal HeLa cells and control shRNA transfected HeLa cells are in lanes 1 and 2. The b-actin mRNA served as an internal
control. (B) The depletion eﬀectiveness in Drosha knockdown stable HepG2 cell lines was analyzed by qRT–PCR. Drosha mRNA was reduced in all
selected stable cell clones, ﬁve of which were shown respectively in bars 3–7 (bar 1: normal HepG2 cells; bar 2: control stably transfected HepG2
cells). shDrosha clone 2 in bar 4 demonstrated a strong downregulation to 95% of Drosha mRNA. (C) Drosha protein was detected by western blot.
(D) miRNA expressions were detected by qRT–PCR. The expression levels of three miRNAs selected randomly, including miR-16, miR-31 and
miR-99a decreased moderately in shDrosha clone 2 and clone 3 compared with normal HepG2 cells and control stably transfected HepG2 cells.
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noma and prostate cancer, CCND1 is often overexpressed
and plays important roles in cancer development (26).
Recent study validated that repression of CCND1 was a
useful strategy to inhibit the growth of tumors, suggesting
CCND1 was a potential anticancer drug target (27).
Reverse screening themiRNAs regulating CCND1
by Luciferase assay
To identify the miRNAs controlling CCND1 expression,
Targetscan software (www.targetscan.org) (28,29) was
used to analyze potential miRNA target sites in 30-UTR
of CCND1. As shown in Figure 2A, the 30-UTR of
Table 2. mRNAs upregulated in Drosha depleted HepG2 cells compared with control transfected cells and normal HepG2 cells
Gene name Ratio of
shDrosha
/no shRNA
Ratio of
shDrosha
/control
shRNA
Function
SPINK5L3 36.15 41.79
SERPINE1 11.18 13.26 Blood coagulation, ﬁbrinolysis, regulation of angiogenesis
CCND1 8.6 2.78 Cell cycle, cell division, fat cell diﬀerentiation
F3 8.04 5.53 Blood coagulation, immune response
GADD45A 7.56 3.4 DNA repair, apoptosis, cell cycle
DUSP5 6.09 3.58 Protein amino acid dephosphorylation
FN1 5.74 2.43 Acute-phase response, cell adhesion, cell migration, metabolic process, response to wounding
STS-1 5.53 3.63
MFAP5 5.27 12.71
SAT 4.91 3.92 Metabolic process
SLC19A2 4.69 3.02 Sensory perception of sound, thiamin transport
ODC1 4.69 3.12 Kidney development, polyamine biosynthetic process, cell proliferation
ANGPTL4 4.43 3.64 Angiogenesis, cell diﬀerentiation, development, apoptosis, lipoprotein lipase activity, response to hypoxia
MATN2 4.35 8.4 Biological process
ADM 4.1 4.32 Cell–cell signaling, circulation, female pregnancy, heart development, cell proliferation
NRG1 4.09 7.04 Blood pressure regulation, cell diﬀerentiation, development, glucose transport, myelination, of transcription
CYR61 4.03 5.53 Anatomical structure morphogenesis, cell adhesion, cell proliferation, chemotaxis,
DKK1 3.81 2.93 Wnt receptor signaling pathway, embryonic limb morphogenesis, multicellular organismal development
ETS1 3.71 2.12 Immune response, cell proliferation, erythrocyte diﬀerentiation, regulation of transcription
CTPS 3.69 2.93 Biosynthetic process, metabolic process, response to drug
RAPGEF2 3.69 5.12 MAPKKK cascade, cAMP-mediated signaling, regulation of small GTPase-mediated signal transduction
SLC7A11 3.65 4.04 Transport, protein complex assembly
CPA4 3.47 3.71 Histone acetylation, proteolysis
ABHD5 3.28 3.44 Lipid metabolic process, proteolysis
ENO2 3.14 6.48 Glycolysis
RND3 3.09 3.32 Actin cytoskeleton organization and biogenesis, cell adhesion, small GTPase-mediated signal transduction
BMP6 3.02 4.31 BMP signaling pathway, development, inﬂammatory response, osteoblast diﬀerentiation, aldosterone
biosynthetic process
CD44 3 2.1 Cell adhesion
PPP1R3F 2.99 4.41
Q9P2H4 2.81 2.63
SLPI 2.75 3.45 Serine-type endopeptidase inhibitor activity
GAD1 2.69 3.26 Carboxylic acid metabolic process, neurotransmitter biosynthetic process, protein-pyridoxal-5-phosphate
linkage, synaptic transmission
IGFBP3 2.61 18.36 Signal transduction, apoptosis, myoblast diﬀerentiation, protein amino acid phosphorylation, cell growth
Q7Z2U1 2.61 2.39
HDHD1A 2.51 2.13 Metabolic process
DNAJC1 2.44 2.24 Proteolysis, protein folding, protein secretion
OSMR 2.36 2.4 Cell proliferation, cell surface receptor linked signal transduction
TMEM50A 2.3 3.07
C21orf34 2.26 3.29
ATF3 2.21 2.08 Regulation of transcription, DNA-dependent
KRT17 2.13 3.37 Biological process, epidermis development
ABCD3 2.12 2.78 Peroxisome organization and biogenesis, transport
LIMA1 2.11 3.33 Actin ﬁlament bundle formation, actin ﬁlament depolymerization, ruﬄe organization and biogenesis
C1orf181 2.09 2.29
CDKN1A 2.09 5.87 Cell cycle arrest, apoptosis, cell proliferation, response to DNA damage stimulus, response to UV
Table 1. Distinct ﬁlters identify various numbers of diﬀerentially
expressed (upregulated and downregulated) probe sets in individual
samples
shDrosha
Clone2/no
shRNA
shDrosha
Clone2/control
shRNA
Overlap
All probes changed (upregulated and downregulated probes)
Changed 1.5-fold 1497 1054 394
Changed 2.0-fold 491 282 90
Upregulated probes
Upregulated 1.5-fold 781 558 221
Upregulated 2.0-fold 281 153 53
Nucleic Acids Research, 2008, Vol. 36, No. 16 5395Figure 2. miR-16 family downregulated CCND1 protein and mRNA by targeting a putative binding site. (A) Human CCND1 30-UTR and its
possible miRNA target sites predicted by targetscan software. Many diﬀerent miRNA seed regions are complementary to the elements of CCND1
30-UTR, among which miR-16 family has two conserved sites. (B) Luciferase assays indicated that miR16 family could downregulate the expression
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to various miRNA seed regions, and these elements carry
the identical sequences in human, mouse, rat, dog and
chicken mRNA orthologues, which suggest that CCND1
could be regulated by diverse miRNAs.
To screen the miRNAs which can genuinely regulate the
expression of CCND1 mRNA, the CCND1 30-UTR was
cloned into a modiﬁed pGL-3 control vector, placing the
30-UTR with most of potential miRNA binding sites
downstream of coding sequence of luciferase. The con-
struct was cotransfected into HepG2 cells with control
plasmid or plasmids expressing miRNAs regulating
CCND1 potentially, which come from a constructed
miRNA expression library (20). The results of luciferase
assays revealed that overexpression of miR-16, miR-195
and miR-424 could reduce the luciferase activity from
the reporter construct containing the CCND1 30-UTR
signiﬁcantly, and that miR-15a and miR-497 could also
reduce the luciferase activity moderately, whereas other
miRNA expression plasmids and control plasmid had no
eﬀect on the luciferase activity (Figure 2B). These results
of reverse screening suggested that miR-16, miR-195 and
miR-424 could regulate the expression of CCND1 by
targeting the complementary sites. And the seed hexamer
of miR-16, miR-195 and miR-424 is identical, which
suggests that they belong to the same miRNA family
and regulate gene expression by targeting the same bind-
ing sites. Additionally, sequence inspection revealed the
presence of two conserved elements complementary to
the seed region of miR-16 family (nucleotides 2–8)
(Figure 2C). To identify which putative target site was
regulated by miR-16 family, two diverse deletants of
CCND1 30-UTR were cloned into the modiﬁed pGL3
control vector, of which the ﬁrst contains putative target
site 1 and the second contains no putative miR-16 target
site at all. Luciferase assays indicated that overexpression
of miR-16, miR-195 and miR-424 could reduce the lucif-
erase activity from the reporter construct containing
wild-type CCND1 30-UTR (containing both putative
binding sites), whereas had no eﬀectiveness on any
deletant of CCND1 30-UTR (Figure 2D). These results
reveal that miR-16, miR-195 and miR-424 may regulate
the expression of CCND1 by targeting putative binding
site 2.
Having established the ability of miR-16 and miR-424
to mediate repression of luciferase via the CCND1
30-UTR, we next assayed their capacity to regulate
the endogenous CCND1. Synthetic miR-16, miR-424
duplex and control Luc-siRNA were transfected to
HepG2 cells. Western blot and qRT–PCR were used
to detect the expression level of CCND1 protein and
mRNA, respectively. qRT–PCR analysis showed a
moderate reduction of CCND1 mRNA in HepG2 cells
overexpressing miR-16 or miR-424 (Figure 2E). miR-16,
miR-195 and miR-424 were downregulated in HepG2 cells
depleted of Drosha (Figure 1D and Figure S1), this could
explain the upregulation of CCND1 mRNA in clone 2
(Table 2). Western blot analysis revealed that miR-16
and miR-424 markedly reduced CCND1 protein levels
compared to Luc-siRNA and mock transfected
cells (Figure 2F). All the results above support the
notion that miR-16 and miR-424 can regulate the expres-
sion of CCND1 directly in vivo.
miR-16family induced cell cycle arrest partially
by regulatingCCND1
CCND1, in association with cyclin-dependent kinase
(CDK4 and CDK6), phosphorylates the Rb, blocking its
growth inhibitory activity, promoting cells to pass through
the R point and thus driving them from G1 phase to S
phase (30). Repression of CCND1 prevents cells from
entering the S phase, causing an accumulation of cells in
G0/G1. However, we detected no G0/G1 accumulation
phenotype in HepG2 cells transfected with miR-16,
miR-424 or siRNA against CCND1, although CCND1
protein levels reduced markedly (data not shown). It is
possible due to insensitivity of HepG2 cells to miR-16
and the depletion of CCND1.
miR-16 family downregulates many transcripts and
negatively regulates cell cycle progression by inducing
the G0/G1 accumulation in A549 cells and some other
cell lines (31). However, no genuine targets regulated by
miR-16 family directly have been identiﬁed. To verify
whether miR-16 family triggered G1 arrest by regulating
the expression of CCND1, these miRNA and siRNA
against CCND1 were transfected into A549 cells. The
results revealed that miR-16, miR-424 and siRNA against
CCND1 could depress the expression of CCND1 in A549
cells as well (Figure 3A). Furthermore, the levels of phos-
phorylated pRb decreased at the same time. Cyclin D1
levels were consistently found to be low in S phase, and
high in G1 and G2 phases (32), but qRT–PCR analysis
suggested that the expression levels of miR-16, miR-195
and miR-424 had no obvious change during the G0/G1, S
and G2/M phases of the cell cycle (Figure S2). Compared
with miR-16 and miR-424, siRNA against CCND1 had
stronger inhibition eﬀectiveness on CCND1; however,
its inhibition eﬀect on pRb was weaker than these
miRNAs (Figure 3A). The results of cell cycle analysis
conﬁrmed that all of miR-16, miR-424 and siRNA against
CCND1 could lead to G1 arrest in A549 cells (Figure 3B).
But, siRNA against CCND1 (37.93%) triggered less
G0/G1-cell accumulation than miR-16 (54.80%) or
miR-424 (51.01%), despite its silencing eﬀect on target
of CCND1. pcDNA3.0 control plasmid and 16 diﬀerent miRNA expressing plasmids were cotransfected with a modiﬁed pGL-3 control vector
containing CCND1 30-UTR. Luciferase assays were performed 48h posttransfection. Histogram shows normalized mean values of relative luciferase
activity form three independent experiments. Normalized luciferase activity in the absence of miRNAs expression vector was set to 100%. Arrows
indicate a signiﬁcant reduction of luciferase activity by miR-16/195/424. (C) Sequence inspection by bioinformatics reveals that target site 1(above)
and target site 2 (below) are two conserved elements complementary to the seed region of miR-16 (nucleotides 2–8). (D) Luciferase assays indicated
that miR-16 family downregulated the expression of CCND1 by targeting putative target site 2. pcDNA3.0 control plasmid, miR-16 expressing
plasmid and miR-424 expressing plasmid were cotransfected with a modiﬁed pGL-3 control vector containing wild-type CCND1 30-UTR or two
deletants of CCND1 30-UTR, respectively. The eﬀectiveness of synthetic miR-16/424 on CCND1 mRNA and protein was respectively analyzed by
qRT–PCR (E) and western blot (F).
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suggest that CCND1 is just one of the targets regulated by
miR-16 family to control cell cycle progression, and some
other targets may be involved in G0/G1 transition, too.
miR-16family regulated theexpressions of CCND3,
CCNE1 and CDK6
The passage of cells through the cell division cycle is regu-
lated by a family of kinases, the cyclin-dependent kinases
(CDKs) and their activating partners, the cyclins.
Diﬀerent cyclin/CDK complexes regulate each of the cell
cycle transitions. The G1/S phase transition is regulated
primarily by D-type cyclins (D1, D2 or D3) in complex
with CDK4/CDK6, and E-type cyclins (E1 or E2) in com-
plex with CDK2. These complexes cooperate in phosphor-
ylating and preventing Rb binding to E2F, thus activating
E2F-mediated transcription and driving cells from G1 into
S phase (27). The results of computational prediction
Figure 3. miR-16 and miR-424 triggered G1 arrest partially by regulating CCND1. (A) The eﬀectiveness of miR-16, miR-424 and siRNA against
CCND1 on CCND1 and pRb was analyzed by western blot, with mock and control Luc-siRNA transfected A549 cells as controls. Antibody against
b-actin was used as a loading control. (B) miR-16 and miR-424 triggered the accumulation of cells at G0/G1 stage. A549 cells were treated with
nocodazole 24h posttransfection and cell cycle distributions were detctected 20h later. 2N, cells having diploid DNA content; 4N, cells having
tetraploid DNA content.
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regulating G1/S transition directly, including CCND1,
CCND2, CCND3, CCNE1, CDK6 and cdc25A, had the
elements complementary to the seed hexamer of miR-16
(Figure S3), which suggested these genes were putative
targets of miR-16 family.
To analyze the eﬀects of miR-16 family on these puta-
tive targets, miR-16 and miR-424 were transfected into
A549 cells, and western blot was used to detect the protein
expression levels of putative targets. As evident from
Figure 4, miR-16 and miR-424 markedly reduced
CCND3, CCNE1 and CDK6 protein levels compared
with mock transfected cells (Figure 4A, C and E). In con-
trast, we observed no decrease in cdc25A protein (data
not shown). The results above indicated that miR-16
family regulated the expressions of CCND3, CCNE1
and CDK6.
To test whether regulation was direct, 30-UTRs of
these selected targets were cloned into the modiﬁed
pGL3-control vector, placing the 30-UTRs with
putative miR-16 binding sites downstream of the
coding sequence of luciferase. Co-transfection with
pcDNA-miR-16 and pcDNA-miR-424 but not
pcDNA3.0 speciﬁcally decreased luciferase levels from
each reporter (Figure 4B, D and F). Mutation in seed
complementary site fully rescued repression for CDK6.
For CCNE1, mutation of the single conserved seed com-
plementary site had only a partial eﬀect (Figure 4D), and
mutations of both seed complementary sites fully rescued
repression for CCNE1, indicating a combination of both
sites eﬀects of miR-16. For CCND3, only mutation of the
ﬁrst putative binding site rescued repression, which sug-
gested that miR-16 regulated CCND3 by targeting the
ﬁrst seed complementary site.
miR-16family triggered G1arrest by regulating aset
ofcell cycle-related genes
To investigate the biological signiﬁcance of these targets
regulated by miR-16 family, we synthesized the siRNAs
against these target mRNAs and transfected them into
A549 cells. The results of western blot displayed that
miR-16 repressed the expression of CCND1, CCND3,
CCNE1 and CDK6 simultaneously, and each siRNA
inhibited its target, respectively (Figure 5A). We then
Figure 4. miR-16 and miR-424 regulated a set of cell cycle genes. Western blot analysis of CCND3 protein(A), CCNE1(C) and CDK6(E) in A549
cells transfected with dsRNA indicated above the lanes. Antibody against b-actin was used as a loading control. Luciferase assays indicated that
miR16 family downregulated the expression of CCND3(B), CCNE1(D) and CDK6(F) directly. pcDNA3.0 control plasmid, miR-16 expressing
plasmid and miR-424 expressing plasmid were cotransfected with luciferase reporter vector containing wild-type 30-UTR of CCND3/CCNE1/
CDK6 and their own diﬀerent mutants of 30-UTR, respectively. For all histograms, mean values are shown and error bars represent SD from
three independent experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5399Figure 5. miR-16-induced G1 arrest in A549 cells by regulating multiple cell cycle genes. (A) The downregulation eﬀectiveness of miR-16 and
siRNAs against diﬀerent genes (lanes 3–7) was analyzed by western blot with antibodies indicated on the left. In lanes 1 and 2, mock and control
Luc-siRNA transfected A549 cells served as controls. Antibody against b-actin was used as a loading control. (B) miR-16 and siRNAs induced G1
arrest in A549 cells. miR-16 triggered more accumulation of cells at G0/G1 stage than siRNAs against CCND1, CCND3, CCNE1 and CDK6,
respectively. A549 cells were treated with nocodazole 24h posttransfection and cell cycle distribution detected 20h later. 2N, cells having diploid
DNA content; 4N, cells having tetraploid DNA content. (C) miR-16 and cell cycle gene expression vectors were cotransfected into A549 cells, and
cell cycle distributions were detctected by ﬂow cytometry.
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As shown in Figure 5B, silencing of these selected miR-16
targets by using siRNAs led to a substantial arrest in G1,
partly phenocopy activation of miR-16. Linsley et al. (31)
reported that siRNA pool targeting CARD10 induced the
accumulation of cells in G0/G1 to the same extent
as miR-16, but our luciferase assay results suggested that
CARD10 was not the genuine target regulated by miR-16
directly (data not shown).
To ﬁnalize the function of miR-16-targeting these genes
in cell cycle, rescue experiments were carried out. Utilizing
pIERS2-EGFP expression vector, CCND1, CCND3,
CCNE1 and CDK6 constructs without wild 30-UTR
were generated. These expression vectors were transiently
cotransfected with miR-16. To remove the inﬂuence of
transient low-transfection eﬃciency, the GFP-positive
A549 cells were selected to perform cell cycle analysis.
As shown in Figure 5C, when miR-16 was cotransfected
with any of these cell cycle genes expression vectors,
G1 arrest eﬀectiveness of miR-16 was partially rescued,
and CCNE1 had the strongest inhibiting eﬀect on the
activity of miR-16.
To conﬁrm the cellular phenotype induced by miR-16
family is not artiﬁcial, we determined whether CCND1
downregulation and G0/G1 cell accumulation phenotype
could be induced by miR-16 family expressed from geno-
mic fragment. A549 cells were transfected with the plas-
mids expressing primary forms of miR-16 or miR-424.
Flow cytometry analysis revealed that these plasmids
could just induce slight G1 arrest in A549 cells (data not
shown). It happened probably as a result of low-transient
transfection eﬃciency. In addition, recombinant adeno-
virus was produced to express miR-195. When A549
cells were infected with Ad-miR-195, the expression level
of miR-195 increased signiﬁcantly (up to 90-fold)
(Figure 6A). Western blot analysis revealed that the
levels of CCND1, CCND3, CCNE1, CDK6 and pRb
decreased in A549 cells infected with Ad-miR-195
Figure 6. miR-195 repressed the expression of multiple cell cycle genes and induces cell cycle arrest. (A) The expression of miR-195 was detected by
qRT–PCR, A549 cells were infected by Ad and Ad-miR-195. (B) The eﬀectiveness of miR-195 on CCND1, CCND3, CCNE1, CDK6 and pRb was
analyzed by western blot. (C) miR-195 induced G1 arrest in A549 cells. A549 cells were treated with nocodazole 48h postinfection and cell cycle
distributions were detected 20h later.
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conﬁrmed that natural form of miR-195 could lead to
G1 arrest in A549 cells (Figure 6C). Taken together,
results above suggest that miR-16 family triggers an accu-
mulation of cells in G0/G1 by regulating multiple down-
stream eﬀectors including CCND1, CCND3, CCNE1 and
CDK6.
DISCUSSION
To date, a large number of miRNAs have been identiﬁed
in several organisms, including vertebrates and plants. In
human, 533 miRNAs were validated (16,17), and some
computational studies estimated that the number of
human miRNAs is as many as 2- to 4-fold higher (33).
However, only a handful of comprehensive studies on
miRNA function have been completed, whereas the func-
tion of most miRNAs remains unknown. One of the main
challenges in identiﬁcation of miRNA function is to iden-
tify the genuine miRNA target gene (or genes) among
many predicted targets.
In this study, we generated the cell lines depleted of
Drosha protein, and indicated that 53 transcripts were
upregulated remarkably in HepG2 cells depleted of
Drosha. Given the roles of Drosha in the miRNA path-
way (2,21,34), these upregulated transcripts may be
regulated by miRNAs. Rehwinkel et al. (19) proﬁled the
expression of mRNAs in Drosophila S2 cells depleted
of Drosha, the results revealed that Drosha knockdown
triggered upregulation of many transcripts. Furthermore,
they concluded that the majority of those transcripts were
genuine miRNA targets. Among these transcripts upregu-
lated in HepG2 cells depleted of Drosha, CCND1 is a key
cell cycle-related gene, and regulates G1/S transition. On
the basis of miRNA expressing library (20), we established
a miRNA targets reverse screening method by using lucif-
erase reporter assay. By this method, multiple miRNAs
including miR-16, miR-195 and miR-424 were identiﬁed
to regulate the expression of CCND1. Furthermore, these
miRNAs triggered G1 cell cycle arrest partially by repress-
ing CCND1 in A549 cells (Figure 3). As all know, not all
miRNA targets are downregulated at mRNA levels, thus,
not all of them can be identiﬁed by the strategy analyzing
mRNA expression in Drosha knockdown cells. Actually,
for any genes we are interested in, this miRNA target
reverse screening method can be used to analyze whether
they are regulated by miRNAs, and screen the miRNAs
regulating these mRNA genes. Using the reverse screening
method, we found that several genes could be regulated
by certain miRNAs, even some target genes could be
regulated by multiple miRNAs simultaneously (data not
shown). All these data suggest that this miRNA targets
reverse screening method is very useful for identifying
miRNA targets, and may play an important role in the
characterization of miRNA function.
Although the biological roles of only a small fraction
of identiﬁed miRNAs have been elucidated to date, the
available evidence has shown that miRNA mutations or
mis-expression correlate with various human cancers and
that miRNAs can function as tumor suppressors and
oncogenes to regulate key pathways involved in cellular
growth control (35). Some miRNAs are involved in tumor
genesis by modulating cell cycle progression (36). For
example, aberrant expression of miR-221/222 was
observed in diverse tumors, such as papillary thyroid
carcinoma (37,38), pancreatic adenocarcinoma and glio-
blastoma (39). Further study revealed that ectopic over-
expression of miR-221/222 repressed the expression of
p27(Kip1) by targeting the binding sites in the 30-UTR
of p27 mRNA and strongly aﬀected cellular growth
potentially by inducing a G1 to S shift in the cell cycle.
These results suggest that miR-221/222 can be regarded as
a new family of oncogenes, directly targeting the tumor
suppressor p27(Kip1), and that their overexpression might
be one of the factors contributing to the oncogenesis and
progression of prostate carcinoma through p27(Kip1)
downregulation (40,41). Recently, miR-34 family mem-
bers have been shown to be directly regulated by the
tumor suppressor, TP53 (42–44). Overexpression of
miR-34 causes cell cycle arrest at G1 phase by downregu-
lation of a signiﬁcantly great number of genes promoting
cell cycle progression. Several downregulated cell cycle
genes (including CCNE2, CDK4 and MET) have been
validated as direct targets by showing miR-34 regulation
of reporters engineered to contain the 30-UTRs of the
respective targets (44). Recently, Schultz et al. (45) have
shown that let-7b regulates CCND1 and induces G1 arrest
in malignant melanoma cells. Our studies have revealed
that miR-34a (46) and miR-16 family can regulate
CCND1 and induce G1 arrest in A549 cells too. To com-
pare their eﬀects on cell cycle, these miRNAs were synthe-
sized and transfected into A549 cells. As shown in
Figure S4, all of let-7b, miR-16 and miR-34a reduced
CCND1 protein level and induced G1 arrest compared
with Luc-siRNA. miR-16 and miR-34a had stronger inhi-
bition eﬀectiveness on CCND1 than let-7b, and miR-16
had the best eﬀect on triggering accumulation of cells in
the G0/G1 phase. Furthermore, compared with siRNA
against CCND1, all these miRNAs had weaker inhibition
eﬀectiveness on CCND1, but triggered more prominent
G0/G1-cell accumulation. These results suggest that all
these miRNAs induce G1 cell cycle arrest by regulating
multiple target genes, rather than a single key target.
miR-16 family negatively regulates cellular growth and
cell cycle progression. They trigger the G0/G1 accumula-
tion phenotype in diverse cell lines, including HCT116,
DLD-1, A549, MCF7 and Tov21G cells (31,36). Here,
we found that miR-16 and miR-424 could regulate the
expression of CCND1 by targeting putative target site
(Figure 2). Further study revealed that several other cell
cycle genes (such as CCND3, CCNE1 and CDK6) could
also be regulated by miR-16 family (Figure 4), and all
these cell cycle genes were involved in G1/S transition.
Flow cytometry assay revealed that depletion of these tar-
gets led to a substantial arrest in G1, partly phenocopy
activation of miR-16 (Figure 5B). All results above indi-
cated that simultaneous silencing of these genes was more
eﬀective on blocking cell cycle progression than deletion
of an individual gene. Taken together, both our results
and ﬁndings of Linsley et al. (31) argue that miR-16 tar-
gets act in concert, rather than individually, to regulate
5402 Nucleic Acids Research, 2008, Vol. 36, No. 16G1/S transition (Figure 7). In other words, multiple tar-
gets regulated by an individual miRNA can act coordi-
nately to regulate the same biological process (36).
Just like siRNA against CCND1, miR-16 family
repressed the expression of CCND1, but led to no
G0/G1 accumulation phenotype in HepG2 cells.
Likewise, miR-16 could not trigger cell cycle arrest in
megakaryocytic cell line MEG-01 (data not shown).
Cimmino et al. (14) reported that miR-16 induced apo-
ptosis by targeting Bcl-2 in MEG-01 cells. However, we
detected no signiﬁcant apoptosis following transfection
with miR-16 in A549 cells. These data suggest that the
eﬀect of miR-16 family on cell cycle arrest and apoptosis
is cell type dependent, that is to say, miR-16 leads to cell
cycle arrest in some types of cells, but induces apoptosis in
others. It is possibly because some types of cells are sensi-
tive to the downregulation of the targets regulated by
miRNA, whereas others are not. Or the deletion, mutation
or editing of binding sites in target mRNAs can also result
in the inactivation of miRNA (47).
All data above argue that miR-16 family may partici-
pate in cell growth control and play tumor-suppressor
roles by regulating cell proliferation and/or apoptosis
pathway in various tumor cells. Both CCND1 (25) and
Bcl-2 (48) play important roles in tumorigenesis, and
serve as speciﬁc tumor therapeutic targets. And siRNAs
against them can inhibit tumor cell growth signiﬁcantly.
Now that miR-16 can regulate multiple target genes
promoting cell growth, including Bcl-2, CCND1,
CCND3, CCNE1 and CDK6, and have stronger inhibi-
tory eﬀectiveness on cell growth than siRNAs against an
individual gene, exogenous expression of miR-16 may be
more eﬀective for tumor therapy than depletion of single
oncogene.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
Chinese State Key Projects for Basic Research
(2006CB0D0807); National 863 plans projects
(2006AA02Z127); Chinese National Natural Science
Foundation project (30500299); Beijing Natural Science
Foundation project (5072039) partially. Funding for
open access charge: Chinese State Key Projects for Basic
Research (2006CB0D0807).
Conﬂict of interest statement. None declared.
REFERENCES
1. Lee,Y., Jeon,K., Lee,J.T., Kim,S. and Kim,V.N. (2002) MicroRNA
maturation: stepwise processing and subcellular localization. EMBO
J., 21, 4663–4670.
2. Lee,Y., Ahn,C., Han,J., Choi,H., Kim,J., Yim,J., Lee,J., Provost,P.,
Radmark,O., Kim,S. et al. (2003) The nuclear RNase III Drosha
initiates microRNA processing. Nature, 425, 415–419.
3. Lund,E., Guttinger,S., Calado,A., Dahlberg,J.E. and Kutay,U.
(2004) Nuclear export of microRNA precursors. Science, 303,
95–98.
4. Yi,R., Qin,Y., Macara,I.G. and Cullen,B.R. (2003) Exportin-5
mediates the nuclear export of pre-microRNAs and short hairpin
RNAs. Genes Dev., 17, 3011–3016.
5. Hammond,S.M., Boettcher,S., Caudy,A.A., Kobayashi,R. and
Hannon,G.J. (2001) Argonaute2, a link between genetic and
biochemical analyses of RNAi. Science, 293, 1146–1150.
6. Gregory,R.I., Chendrimada,T.P., Cooch,N. and Shiekhattar,R.
(2005) Human RISC couples microRNA biogenesis and posttran-
scriptional gene silencing. Cell, 123, 631–640.
7. Ambros,V. (2004) The functions of animal microRNAs. Nature,
431, 350–355.
8. Olsen,R.C. and Ambros,V. (1999) The lin-4 regulatory RNA
controls developmental timing in Caenorhabditis elegans by
blocking Lin-14 protein synthesis after the initiation of translation.
Dev. Biol., 216, 671–680.
9. Slack,F.J., Basson,M., Liu,Z., Ambros,V., Horvitz,H.R. and
Ruvkun,G. (2000) The lin-41 RBCC gene acts in the C. elegans
heterchronic pathway between the let-7 regulatory RNA and the
LIN-29 transcription factor. Mol. Cell, 5, 659–669.
10. Lim,L.P., Lau,N.C., Garrett-Engele,P., Grimson,A., Schelter,J.M.,
Castle,J., Bartel,D.P., Linsley,P.S. and Johnson,J.M. (2005)
Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature, 433, 769–773.
11. Bagga,S., Bracht,J., Hunter,S., Massirer,K., Holtz,J., Eachus,R. and
Pasquinelli,A.E. (2005) Regulation by let-7 and lin-4 miRNAs
results in target mRNA degradation. Cell, 122, 553–563.
12. Calin,G.A., Dumitru,C.D., Shimizu,M., Bichi,R., Zupo,S., Noch,E.,
Aldler,H., Rattan,S., Keating,M., Rai,K. et al. (2002) Frequent
deletions and downregulation of micro-RNA genes miR15 and
miR16at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad.
Sci. USA, 99, 15524–15529.
13. Bottoni,A., Piccin,D., Tagliati,F., Luchin,A., Zatelli,M.C. and degli
Uberti,E.C. (2005) miR-15a and miR-16-1 down-regulation in
pituitary adenomas. J. Cell Physiol., 204, 280–285.
14. Cimmino,A., Calin,G.A., Fabbri,M., Iorio,M.V., Ferracin,M.,
Shimizu,M., Wojcik,S.E., Aqeilan,R.I., Zupo,S., Dono,M. et al.
(2005) miR-15 and miR-16 induce apoptosis by targeting BCL2.
Proc. Natl Acad. Sci. USA, 102, 13944–13949.
15. Martello,G., Zacchigna,L., Inui,M., Montagner,M., Adorno,M.,
Mamidi,A., Morsut,L., Soligo,S., Tran,U., Dupont,S. et al. (2007)
MicroRNA control of Nodal signalling. Nature, 449, 183–188.
16. Griﬃths-Jones,S., Grocock,R.J., van Dongen,S., Bateman,A. and
Enright,A.J. (2006) miRBase: microRNA sequences, targets and
gene nomenclature. Nucleic Acids Res., 34, D140–D144.
Figure 7. miR-16 family modulates G1/S transition by regulating
Cdk4/6-cyclin D complexes and Cdk2-cyclin E complexes. The G1/S
phase transition is regulated primarily by D-type Cyclins (D1, D2 or
D3) in complex with CDK4/CDK6, and E-type Cyclins (E1 or E2) in
complex with CDK2. These complexes cooperate in phosphorylating
and preventing Rb binding to E2F, thus activating E2F-mediated tran-
scription and driving cells from G1 into S phase. miR-16 family control
the expression levels of Cyclin D1, Cyclin D3, Cyclin E1 as well as
CDK6, inactivate Cdk2/4/6 kinases, and thus prevent phosphorylation
of Rb proteins. Moreover, miR-16 can induce apoptosis by downregu-
lation of antiapoptosis protein Bcl-2.
Nucleic Acids Research, 2008, Vol. 36, No. 16 540317. Griﬃths-Jones,S., Saini,H.K., Dongen,S.V. and Enright,A.J. (2008)
miRBase: tools for microRNA genomics. Nucleic Acids Res., 36,
D154–D158.
18. Kru ¨ tzfeldt,J., Poy,M.N. and Stoﬀel,M. (2006) Strategies to deter-
mine the biological function of microRNAs. Nat. Genet., 38,
S14–S19.
19. Rehwinkel,J., Natalin,P., Stark,A., Brennecke,J., Cohen,S.M. and
Izaurralde,E. (2006) Genome-wide analysis of mRNAs regulated by
Drosha and Argonaute proteins in Drosophila melanogaster.
Mol. Cell Biol., 26, 2965–2975.
20. Cui,J., Fu,H., Feng,J., Zhu,J., Tie,Y., Xing,R. and Zheng,X. (2007)
The construction of miRNA expression library for human. Prog.
Biochem. Biophys., 34, 389–394.
21. Gregory,R.I., Yan,K.P., Amuthan,G., Chendrimada,T.,
Doratotaj,B., Cooch,N. and Shiekhattar,R. (2004) The
Microprocessor complex mediates the genesis of microRNAs.
Nature, 432, 235–240.
22. Fu,H.J., Zhu,J., Yang,M., Zhang,Z.Y., Tie,Y., Jiang,H., Sun,Z.X.
and Zheng,X.F. (2006) A novel method to monitor the expression
of microRNAs. Mol. Biotechnol., 32, 197–204.
23. He,T.C., Zhou,S., da Costa,L.T., Yu,J., Kinzler,K.W. and
Vogelstein,B. (1998) A simpliﬁed system for generating recombinant
adenoviruses. Proc. Natl Acad. Sci. USA, 95, 2509–2514.
24. Kim,V.N. (2005) MicroRNA biogenesis: coordinated cropping and
dicing. Nat. Rev. Mol. Cell Biol., 6, 376–385.
25. Alao,J.P. (2007) The regulation of cyclin D1 degradation: roles in
cancer development and the potential for therapeutic invention.
Mol. Cancer, 6, 24.
26. Fu,M., Wang,C., Li,Z., Sakamaki,T. and Pestell,R.G. (2004) Cyclin
D1: normal and abnormal functions. Endocrinology, 145,
5439–5447.
27. Grillo,M., Bott,M.J., Khandke,N., McGinnis,J.P., Miranda,M.,
Meyyappan,M., Rosfjord,E.C. and Rabindran,S.K. (2006)
Validation of cyclin D1/CDK4 as an anticancer drug target in
MCF-7 breast cancer cells: eﬀect of regulated overexpression of
cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1
and CDK4 expression. Breast Cancer Res. Treat., 95, 185–194.
28. Lewis,B.P., Burge,C.B. and Bartel,D.P. (2005) Conserved seed
pairing,often ﬂanked by adenosines,indicates that thousands of
human genes are microRNA targets. Cell, 120, 15–20.
29. Grimson,A., Farh,K.K., Johnston,W.K., Garrett-Engele,P.,
Lim,L.P. and Bartel,D.P. (2007) MicroRNA targeting speciﬁcity in
mammals: determinants beyond seed pairing. Mol. Cell, 27, 91–105.
30. Ortega,S., Malumbres,M. and Barbacid,M. (2002) Cyclin
D-dependent kinases, INK4 inhibitors and cancer. Biochim.
Biophys. Acta, 1602, 73–87.
31. Linsley,P.S., Schelter,J., Burchard,J., Kibukawa,M., Martin,M.M.,
Bartz,S.R., Johnson,J.M., Cummins,J.M., Raymond,C.K., Dai,H.
et al. (2007) Transcripts targeted by the microRNA-16 family
cooperatively regulate cell cycle progression. Mol. Cell Biol., 27,
2240–2252.
32. Stacey,D.W. (2003) Cyclin D1 serves as a cell cycle regulatory
switch in actively proliferating cells. Curr. Opin. Cell Biol., 15,
158–163.
33. Bentwich,I., Avniel,A., Karov,Y., Aharonov,R., Gilad,S., Barad,O.,
Barzilai,A., Einat,P., Einav,U., Meiri,E. et al. (2005) Identiﬁcation
of hundreds of conserved and nonconserved human microRNAs.
Nat. Genet., 37, 766–770.
34. Denli,A.M., Tops,B.B., Plasterk,R.H., Ketting,R.F. and
Hannon,G.J. (2004) Processing of primary microRNAs by the
microprocessor complex. Nature, 432, 231–235.
35. Esquela-Kerscher,A. and Slack,F.J. (2006) Oncomirs – microRNAs
with a role in cancer. Nat. Rev. Cancer, 6, 259–269.
36. Carleton,M., Cleary,M.A. and Linsley,P.S. (2007) MicroRNAs and
cell cycle regulation. Cell Cycle, 6, 2127–2132.
37. He,H., Jazdzewski,K., Li,W., Liyanarachchi,S., Nagy,R., Volinia,S.,
Calin,G.A., Liu,C.G., Franssila,K., Suster,S. et al. (2005) The role
of microRNA genes in papillary thyroid carcinoma. Proc. Natl
Acad. Sci. USA, 102, 19075–19080.
38. Pallante,P., Visone,R., Ferracin,M., Ferraro,A., Berlingieri,M.T.,
Troncone,G., Chiappetta,G., Liu,C.G., Santoro,M., Negrini,M.
et al. (2006) MicroRNA deregulation in human thyroid papillary
carcinomas. Endocr. Relat. Cancer, 13, 497–508.
39. Ciafre ` ,S.A., Galardi,S., Mangiola,A., Ferracin,M., Liu,C.G.,
Sabatino,G., Negrini,M., Maira,G., Croce,C.M. and Farace,M.G.
(2005) Extensive modulation of a set of microRNAs in primary
glioblastoma. Biochem. Biophys. Res. Commun., 334, 1351–1358.
40. le Sage,C., Nagel,R., Egan,D.A., Schrier,M., Mesman,E.,
Mangiola,A., Anile,C., Maira,G., Mercatelli,N., Ciafre ` ,S.A. et al.
(2007) Regulation of the p27Kip1 tumor suppressor by miR-221
and miR-222 promotes cancer cell proliferation. EMBO J., 26,
3699–3708.
41. LinksGalardi,S., Mercatelli,N., Giorda,E., Massalini,S.,
Frajese,G.V., Ciafre ` ,S.A. and Farace,M.G. (2007) miR-221 and
miR-222 expression aﬀects the proliferation potential of human
prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem.,
282, 23716–23724.
42. Raver-Shapira,N., Marciano,E., Meiri,E., Spector,Y., Rosenfeld,N.,
Moskovits,N., Bentwich,Z. and Oren,M. (2007) Transcriptional
activation of miR-34a contributes to p53–mediated apoptosis. Mol.
Cell, 26, 731–743.
43. Chang,T.C., Wentzel,E.A., Kent,O.A., Ramachandran,K.,
Mullendore,M., Lee,K.H., Feldmann,G., Yamakuchi,M.,
Ferlito,M., Lowenstein,C.J. et al. (2007) Transactivation of
miR-34a by p53 broadly inﬂuences gene expression and promotes
apoptosis. Mol. Cell, 26, 745–752.
44. He,L., He,X., Lim,L.P., de Stanchina,E., Xuan,Z., Liang,Y.,
Xue,W., Zender,L., Magnus,J., Ridzon,D. et al. (2007) A
microRNA component of the p53 tumour suppressor network.
Nature, 447, 1130–1134.
45. Schultz,J., Lorenz,P., Gross,G., Ibrahim,S. and Kunz,M. (2008)
MicroRNA let-7b targets important cell cycle molecules in malig-
nant melanoma cells and interferes with anchorage-independent
growth. Cell Res., 18, 549–557.
46. Sun,F., Fu,H., Liu,Q., Tie,Y., Zhu,J., Xing,R., Sun,Z. and
Zheng,X. (2008) Downregulation of CCND1 and CDK6 by
miR-34a induces cell cycle arrest. FEBS Lett., 582, 1564–1568.
47. Huang,J., Liang,Z., Yang,B., Tian,H., Ma,J. and Zhang,H. (2007)
Derepression of microRNA-mediated protein translation inhibition
by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-
like 3G (APOBEC3G) and its family members. J. Biol. Chem., 282,
33632–33640.
48. Ghobrial,I.M., Witzig,T.E. and Adjei,A.A. (2005) Targeting
apoptosis pathways in cancer therapy. CA Cancer J. Clin., 55,
178–194.
5404 Nucleic Acids Research, 2008, Vol. 36, No. 16